Suprefort®
Diabetes mellitus type II occurred in patients without any clinical manifestations and was diagnosed
based on an increase in glucose level in the peripheral blood, taking into account an unbalanced diet.
The control group consisted of 17 patients prescribed medication using conventional treatment. 22
patients included in the primary group, in addition to traditional therapy, including antihyperglycemic
agents, received 1 capsule of SUPREFORT® 2 times a day before meals for 15 days.
RESEARCH METHODS
The patients’ complaints were assessed in dynamics, a general clinical examination of blood and urine,
and a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany) were
carried out. The duodenal contents were examined. A glucose tolerance test was performed.
RESEARCH RESULTS
It was found that the use of SUPREFORT® in patients with chronic pancreatitis promoted an increase
in appetite and a decrease in the frequency of dyspeptic disorders.
Influence of SUPREFORT® on the activity of digestive enzymes in Table 2
patients with chronic pancreatitis.
Indicator Before Treatment After Treatment with Conventional After Treatment with
Means Suprefort®
Trypsin, (mmol/l) 2,14±0,09 2,72±0,12 2,9±0,1
α-amylase, kg / (h•l) 5,2±0,4 5,7±0,3 6,1±0,4
In a laboratory study of the duodenal contents, an initial decrease in the activity of pancreatic enzymes
was noted (Table 2). As a result of the use of SUPREFORT®, there was a tendency to an increase in the
activity of pancreatic enzymes, which correlated with an improvement in clinical symptoms.
In patients with type II diabetes mellitus, SUPREFORT® was used under the control of a glucose tolerance
test. After the sugar load, it was found that the patients had a characteristic glycemic curve. In addition
to the conventional treatment, patients of the primary group were prescribed SUPREFORT® 1 capsule
2 times a day before meals for 10 days. It was shown that after the use of SUPREFORT®, when the test
was performed in the second hour of the study, a gradual decrease in blood glucose levels was observed.
Normalization of blood glucose levels was achieved in all patients 5-10 days after starting the drug. None
of the patients received an increase in the dosage of antihyperglycemic drugs, 12 patients (54.5%) had
a reduced dose of conventional medications, and in 7 patients (31.8%), the blood glucose level did not
exceed normal values without the use of antidiabetic drugs. The indicators remained at the initial level
in 3 patients (13.6%). It should be noted that the indicator of glucose in the blood of patients of the
primary group stabilized during the next 2-3 months after the end of the course of treatment (Table 3).
Influence of SUPREFORT® on blood glucose after carbohydrate load in patients Table 3
with type II diabetes mellitus.
Blood glucose Control Group Primary Group
(mmol/l)
Before Treatment After Treatment Before Treatment After Treatment with
with Conventional Suprefort®
Methods
On an empty stomach 8,2±0,9 6,6±0,4* 7,9±1,1 5,8±0,3*
2 hours after glucose intake 12,7±0,4 9,4±0,5 11,6±0,3 7,0±0,8* **
* P <0.05 - significant compared with the indicator before treatment;
** P <0.05 - significant compared with the indicator in patients of the control group.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.